{"id":"NCT01117012","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Rollover Study of VX-770 in Cystic Fibrosis Subjects","officialTitle":"An Open-Label, Rollover Study to Evaluate the Long Term Safety and Efficacy of VX-770 in Subjects With Cystic Fibrosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2014-05","completion":"2014-05","firstPosted":"2010-05-05","resultsPosted":"2015-07-07","lastUpdate":"2015-07-07"},"enrollment":192,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Ivacaftor","otherNames":["VX-770"]}],"arms":[{"label":"VX-770","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study was to evaluate the safety of long-term VX-770 treatment in participants with cystic fibrosis (CF). The secondary objective of the study was to evaluate the efficacy of long-term VX-770 treatment in subjects with CF.","primaryOutcome":{"measure":"Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Study 105: Day 1 up to Week 168","effectByArm":[{"arm":"VX-770","deltaMin":190,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":58,"countries":["United States","Australia","Canada","Czechia","France","Germany","Ireland","United Kingdom"]},"refs":{"pmids":["25311995"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":70,"n":192},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","Cough","Upper respiratory tract infection","Headache","Nasopharyngitis"]}}